

April 25, 2023

Dear Provider:


Effective July 1, 2023, our New Drug to Market (NDTM) Medical Policy is archived.

Beginning July 1, 2023, Optum Rx will perform prior approval reviews for drugs new to market for both pharmacy and drugs administered in a physician's office. Below is an overview of the process and changes:

- Drugs new to market require prior approval
 - Note: drugs are no longer considered investigational for a six-month period after Federal Drug Administration (FDA) approval, prior approval can be requested through Optum Rx as soon as the drug is approved by the FDA.
- Use the existing Optum Rx prior approval request methods:
 - Web – CoverMyMeds
 - Fax – (844) 403-1029
 - Phone – (800) 313-7879
- Optum will follow the NDTM criteria unless there are specific criteria available for the drug.
- The formulary will list NDTM as needing prior approval.
- Monthly, the list of drugs requiring prior approval will be updated to include any NDTM
 - Note: Any drug that has been recently FDA approved requires prior approval. If you are unsure if the drug is a new drug to the market and/or do not see the drug listed as requiring prior approval, please call Optum Rx (866) 227-7849

Thank you for your time. If you have any questions regarding this notice, feel free to contact your provider relations consultant. If you are not sure who that is, please email providerrelations@bcbsvt.com or call (888) 449-0443 option 1 and you will be directed to the appropriate person. Business hours are Monday through Friday from 8 a.m. to 4:30 p.m., except holidays.

Sincerely,



Lou McLaren
Director, Provider Services